---
title: "AbCellera Biologics Inc. (ABCL.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ABCL.US.md"
symbol: "ABCL.US"
name: "AbCellera Biologics Inc."
industry: "Life Sciences Tools and Services"
datetime: "2026-05-19T21:36:44.836Z"
locales:
  - [en](https://longbridge.com/en/quote/ABCL.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ABCL.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ABCL.US.md)
---

# AbCellera Biologics Inc. (ABCL.US)

## Company Overview

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.

| Item | Detail |
|------|--------|
| Industry | Life Sciences Tools and Services |
| Exchange | US Market |
| Website | [www.abcellera.com](https://www.abcellera.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:12.000Z

**Overall: C (0.46)**

**Industry**: Life Sciences Tools and Services

| Metric | Value |
|--------|-------|
| Industry Ranking | 28 / 59 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 242.68% |  |
| Net Profit YoY | 14.24% |  |
| P/B Ratio | 1.35 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1269902179.52 |  |
| Revenue | 79208000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -14.68% | E |
| Profit Margin | -181.74% | E |
| Gross Margin | 100.00% | A |
| Revenue YoY | 242.68% | A |
| Net Profit YoY | 14.24% | C |
| Total Assets YoY | -2.76% | D |
| Net Assets YoY | -8.30% | D |
| Cash Flow Margin | 106.47% | C |
| OCF YoY | 242.68% | A |
| Turnover | 0.06 | E |
| Gearing Ratio | 28.23% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - AbCellera Biologics Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "242.68%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "14.24%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.35",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "1269902179.52",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "79208000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-14.68%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-181.74%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "242.68%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "14.24%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "-2.76%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-8.30%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "106.47%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "242.68%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.06",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "28.23%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -8.82 | 47/59 | - | - | - |
| PB | 1.35 | 17/59 | 1.39 | 1.18 | 1.06 |
| PS (TTM) | 16.03 | 54/59 | 48.43 | 32.41 | 18.52 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | ChromaDex (CDXC.US) | A | A | A | B | A | A |
| 02 | Agilent Tech (A.US) | A | C | B | C | C | B |
| 03 | West Pharmaceutical (WST.US) | B | B | B | B | B | B |
| 04 | Illumina (ILMN.US) | A | C | B | D | C | B |
| 05 | WuXi Biologics (WXXWY.US) | B | B | C | A | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-12T04:00:00.000Z

Total Analysts: **9**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 7 | 78% |
| Overweight | 1 | 11% |
| Hold | 1 | 11% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 4.05 |
| Highest Target | 12.00 |
| Lowest Target | 7.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ABCL.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ABCL.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ABCL.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ABCL.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**